Singh Sanminder, Armstrong April W
University of California Davis School of Medicine, University of California, Davis, Sacramento, California, USA.
Keck School of Medicine of USC, University of Southern California, Los Angeles, California, USA.
Semin Cutan Med Surg. 2018 Sep;37(3):163-166. doi: 10.12788/j.sder.2018.046.
Psoriasis is chronic inflammatory skin condition that imposes a significant physical and psychosocial burden on patients. Moderate to severe psoriasis often requires systemic treatments, including oral systemic therapies and biologics. An addition to the treatment repository for psoriasis is oral small molecules, which include apremilast, tofacitinib, and ponesimod. Of these 3 medications, only apremilast is currently approved for the treatment of psoriasis. Long-term safety data for apremilast suggest that it has a tolerable safety profile and leads to significant improvement in patients with psoriasis; however, there are few head-to-head comparisons with other oral systemic medications. Tofacitinib and ponesimod have demonstrated clinical efficacy in treating psoriasis; however, further studies are required to understand the benefit-risk profile of these medications in psoriasis patients.
银屑病是一种慢性炎症性皮肤病，给患者带来了巨大的身体和心理社会负担。中度至重度银屑病通常需要全身治疗，包括口服全身疗法和生物制剂。口服小分子药物是银屑病治疗药物库的新增药物，其中包括阿普米拉斯、托法替布和波尼莫德。在这三种药物中，目前只有阿普米拉斯被批准用于治疗银屑病。阿普米拉斯的长期安全性数据表明，它具有可耐受的安全性，可使银屑病患者有显著改善；然而，与其他口服全身药物的直接比较很少。托法替布和波尼莫德在治疗银屑病方面已显示出临床疗效；然而，需要进一步研究以了解这些药物在银屑病患者中的获益风险情况。
